Project No. 04

Modelling Prostate Cancer

Creating sophisticated, world-first models of advanced prostate cancer to accelerate drug development

S c r o l l   R i g h t

The Project

This project was launched as a result of Dr Williamson's work. It is creating sophisticated in-vivo models of advanced prostate cancer.

How?

The team is developing innovative, world-first models to test the effectiveness of new treatments for metastatic prostate cancer, to see if they are good enough and safe enough to be tested in humans.

What will this achieve?

The primary purpose of the models is to test the treatments being developed by other PCRC scientists. Better models of prostate cancer will also help us to better understand the disease.

The Future

The scientists will continue to develop in-vivo models of prostate cancer which will help to develop better therapies and get them into patients much faster.

The Project

This project was launched as a result of Dr Williamson's work. It is creating sophisticated in-vivo models of advanced prostate cancer.

How?

The team is developing innovative, world-first models to test the effectiveness of new treatments for metastatic prostate cancer, to see if they are good enough and safe enough to be tested in humans.

What will this achieve?

The primary purpose of the models is to test the treatments being developed by other PCRC scientists. Better models of prostate cancer will also help us to better understand the disease.

The Future

The scientists will continue to develop in-vivo models of prostate cancer which will help to develop better therapies and get them into patients much faster.

Project Start

October 2017

Research Facility

European Cancer Stem Cell Research Institute, Cardiff University

Budget

£87,000/year

End

October 2020

Professor Matthew Smalley

Team Leader

Matt was awarded a PhD at the Institute of Cancer Research and then worked at the Hammersmith Hospital, the ICR and the Netherlands Cancer Institute. Following research with Breast Cancer Now, he moved to Cardiff in 2012, and became Director of the European Cancer Stem Cell Research Institute at the beginning of 2018. His team works on normal and breast cancer stem cells as well as models of breast and prostate cancer. He is particularly interested in identifying similarities in biology between different sorts of cancer.

Dr Boris Shorning

Postdoctoral Research Scientist

Boris works at Cardiff University on the PCRC-funded project, investigating the role of Plexin B1 in the spread of prostate cancer. He is interested in biochemical pathways involved in the development and spread of cancer. Boris is originally from Volgograd, Russia, he did his PhD in Moscow and he worked at Edinburgh University before coming to Cardiff.

Sarah Martin

Technician

Sarah is the newest recruit to the team and is a technician with extensive experience of cancer model systems. She will be supporting Boris’ work testing novel prostate cancer therapies.

Help us fund a future for men and their families

As a small charity, we can focus the majority of our funds on research.

Support Us

Support the Modelling Prostate Cancer Project

Any donation you can make will help us fund this cutting-edge, life-saving research.

Press enter or esc to cancel